XORTX Therapeutics Book Value Per Share vs. Total Debt

XRTX Stock   1.75  0.01  0.57%   
Based on XORTX Therapeutics' profitability indicators, XORTX Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess XORTX Therapeutics' ability to earn profits and add value for shareholders.
 
Book Value Per Share  
First Reported
2010-12-31
Previous Quarter
3.08869707
Current Value
1.66
Quarterly Volatility
3.46311087
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, XORTX Therapeutics' Payables Turnover is fairly stable compared to the past year. Income Quality is likely to climb to 2.37 in 2024, whereas Book Value Per Share is likely to drop 1.66 in 2024.
For XORTX Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of XORTX Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well XORTX Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between XORTX Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of XORTX Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.
Please note, there is a significant difference between XORTX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if XORTX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XORTX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

XORTX Therapeutics Total Debt vs. Book Value Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining XORTX Therapeutics's current stock value. Our valuation model uses many indicators to compare XORTX Therapeutics value to that of its competitors to determine the firm's financial worth.
XORTX Therapeutics is rated first in book value per share category among its peers. It is rated first in total debt category among its peers making up about  355,701  of Total Debt per Book Value Per Share. At this time, XORTX Therapeutics' Book Value Per Share is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the XORTX Therapeutics' earnings, one of the primary drivers of an investment's value.

XORTX Total Debt vs. Book Value Per Share

Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

XORTX Therapeutics

Book Value per Share

 = 

Common Equity

Average Shares

 = 
2.32 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

XORTX Therapeutics

Total Debt

 = 

Bonds

+

Notes

 = 
825.94 K
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

XORTX Total Debt vs Competition

XORTX Therapeutics is rated first in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 962,061. XORTX Therapeutics totals roughly 825,938 in total debt claiming about 86% of equities under Health Care industry.
Total debt  Capitalization  Valuation  Revenue  Workforce

XORTX Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in XORTX Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, XORTX Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of XORTX Therapeutics' change in net profit over the period of time. It can combine multiple indicators of XORTX Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Net Loss-8.5 M-8.1 M
Net Interest Income253.5 K266.2 K
Operating Income-6 M-5.7 M
Net Loss-2.2 M-2.3 M
Income Before Tax-2.2 M-2.3 M
Total Other Income Expense Net3.6 M3.8 M
Net Loss-2.2 M-2.3 M
Interest Income255.2 K196.1 K
Change To Netincome-4.1 M-3.9 M
Net Loss(1.44)(1.52)
Income Quality 2.26  2.37 

XORTX Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on XORTX Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of XORTX Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the XORTX Therapeutics' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in XORTX Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Transformation Now

   

Price Transformation

Use Price Transformation models to analyze the depth of different equity instruments across global markets
All  Next Launch Module

Use Investing Themes to Complement your XORTX Therapeutics position

In addition to having XORTX Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Copper Thematic Idea Now

Copper
Copper Theme
Companies involved in production of copper. The Copper theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Copper Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.